Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameVoglibose
Accession NumberDB04878
Typesmall molecule
Groupsapproved, investigational
Description

Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix. [Wikipedia]

Structure
Thumb
SynonymsNot Available
SaltsNot Available
Brand names
NameCompany
BasenTakeda Chemical Industries
GlustatNot Available
VocarbNot Available
VolixRanbaxy labs
Brand mixturesNot Available
CategoriesNot Available
CAS number83480-29-9
WeightAverage: 267.2762
Monoisotopic: 267.131802031
Chemical FormulaC10H21NO7
InChI KeyInChIKey=FZNCGRZWXLXZSZ-CIQUZCHMSA-N
InChI
InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
IUPAC Name
(1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
SMILES
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassOrganooxygen Compounds
ClassAlcohols and Polyols
SubclassCyclic Alcohols and Derivatives
Direct parentAminocyclitols and Derivatives
Alternative parentsCyclohexanols; Tertiary Alcohols; 1,2-Diols; 1,2-Aminoalcohols; Polyamines; Primary Alcohols; Dialkylamines
Substituentscyclohexanol; tertiary alcohol; 1,2-diol; secondary alcohol; polyol; 1,2-aminoalcohol; secondary amine; secondary aliphatic amine; polyamine; primary alcohol; organonitrogen compound; amine
Classification descriptionThis compound belongs to the aminocyclitols and derivatives. These are cyclitols with at least one hydroxyl group replace by an amino group.
Pharmacology
IndicationFor the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
PharmacodynamicsVoglibose, an alpha-glucosidase inhibitor, is a synthetic compound with potent and enduring therapeutic efficacies against disorders of sensory, motor and autonomic nerve systems due to diabetes mellitus. The drug was approved in Japan in 1994 for the treatment of diabetes, and it is under further investigation by Takeda for the treatment of impaired glucose tolerance. Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of complex carbohydrates (such as starch). Complex carbohydrates are normally converted into simple sugars (monosaccharides) which can be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar.
Mechanism of actionAlpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level. (From Drug Therapy in Nursing, 2nd ed)
AbsorptionSlowly and poorly absorbed
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Little metabolism occurs and no metabolites have as yet been identified.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.6431
Blood Brain Barrier - 0.9478
Caco-2 permeable - 0.7878
P-glycoprotein substrate Non-substrate 0.6439
P-glycoprotein inhibitor I Non-inhibitor 0.8759
P-glycoprotein inhibitor II Non-inhibitor 0.918
Renal organic cation transporter Non-inhibitor 0.873
CYP450 2C9 substrate Non-substrate 0.812
CYP450 2D6 substrate Non-substrate 0.8224
CYP450 3A4 substrate Non-substrate 0.663
CYP450 1A2 substrate Non-inhibitor 0.8853
CYP450 2C9 substrate Non-inhibitor 0.9232
CYP450 2D6 substrate Non-inhibitor 0.9324
CYP450 2C19 substrate Non-inhibitor 0.9288
CYP450 3A4 substrate Non-inhibitor 0.9856
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9737
Ames test Non AMES toxic 0.9132
Carcinogenicity Non-carcinogens 0.9361
Biodegradation Not ready biodegradable 0.8142
Rat acute toxicity 1.1572 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9395
hERG inhibition (predictor II) Non-inhibitor 0.9532
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
Statesolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
water solubility1.90e+02 g/lALOGPS
logP-2.3ALOGPS
logP-4.9ChemAxon
logS-0.15ALOGPS
pKa (strongest acidic)12.46ChemAxon
pKa (strongest basic)7.66ChemAxon
physiological charge1ChemAxon
hydrogen acceptor count8ChemAxon
hydrogen donor count8ChemAxon
polar surface area153.64ChemAxon
rotatable bond count5ChemAxon
refractivity59.55ChemAxon
polarizability26.02ChemAxon
number of rings1ChemAxon
bioavailability1ChemAxon
rule of fiveNoChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Heinz G. Floss, Sungsook Lee, Ingo Tornus, “Valiolone, a method of preparing it, and its use to prepare acarbose and voglibose.” U.S. Patent US6150568, issued October, 1995.

US6150568
General Reference
  1. Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T: Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes. Diabet Med. 2007 Sep;24(9):962-8. Epub 2007 May 17. Pubmed
  2. Kurebayashi S, Watada H, Tanaka Y, Kawasumi M, Kawamori R, Hirose T: Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. Endocr J. 2006 Apr;53(2):213-7. Pubmed
  3. Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Suganami T, Kuzuya H, Ogawa Y: An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2006 Jun;55(6):786-93. Pubmed
External Links
ResourceLink
KEGG DrugD01665
PubChem Compound444020
PubChem Substance46504462
ChemSpider392046
BindingDB50263044
Therapeutic Targets DatabaseDAP001104
PharmGKBPA164752433
WikipediaVoglibose
ATC CodesA10BF03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

1. Maltase-glucoamylase, intestinal

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Maltase-glucoamylase, intestinal O43451 Details

References:

  1. Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Suganami T, Kuzuya H, Ogawa Y: An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2006 Jun;55(6):786-93. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  3. Matsumura M, Monden T, Miyashita Y, Kawagoe Y, Shimizu H, Nakatani Y, Domeki N, Yanagi K, Ikeda S, Kasai K: Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6. Epub 2009 Jun 30. Pubmed
  4. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K: Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother. 2010 Feb;11(2):169-76. Pubmed
  5. Iwasa M, Kobayashi H, Yasuda S, Kawamura I, Sumi S, Yamada Y, Shiraki T, Yamaki T, Ushikoshi H, Aoyama T, Nishigaki K, Takemura G, Fujiwara T, Fujiwara H, Minatoguchi S: Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol. 2010 Jun;55(6):625-34. Pubmed
  6. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M: Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009 May 1;609(1-3):148-54. Epub 2009 Mar 10. Pubmed

Comments
Drug created on October 20, 2007 12:23 / Updated on September 16, 2013 17:26